New study tests better insulin dosing for kids with diabetes
NCT ID NCT04124302
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 76 children with type 1 diabetes to see if a different way of calculating insulin doses before meals could improve blood sugar control. The children used their usual rapid-acting insulin (glulisine, aspart, or lispro) via a pump. The goal was to find which method leads to fewer blood sugar spikes after eating.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Insulin (glulisine, aspart, or lispro)
- What this could lead to
- If successful, this could help children with type 1 diabetes better manage their blood sugar after meals, reducing highs and lows.
- What could go wrong
- This is a small, completed study comparing existing insulin types and dosing methods. It does not test a new treatment, so any improvements may be modest and not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
76 people
The number who actually took part.
- Started
-
Oct 2019
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
10 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * duration of type 1 diabetes longer than 12 months * insulin pump therapy longer than 3 months * treated by the same type of insulin longer than 3 months * written informed consent by patients and parents Exclusion Criteria: * celiac disease * diabetes related complications (e.g. nephropathy) * any disease judged by the investigator to affect the trial * withdrawal of consent to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Warsaw Medical University
Warsaw, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a glucose app that predicts lows calm diabetes fears?
- Could type 1 diabetes hide liver problems in children?
- Can a Weight-Loss drug slow stomach emptying in type 1 diabetes?
- Can pressurized oxygen tame blood sugar spikes?
- Could a virtual life-coach program help young adults tame type 1 diabetes?
- Can Real-World data improve diabetes care in pregnancy?